DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Pediatrics
Endroit courant :
> This Story

starstarstarstarstar (1)
Ouverture ou Registre to rate this News Story
Forward Printable StoryPrint Comment




MRI Homepage

MR and ultrasound biopsies combined can detect prostate cancers, says study Detect up to 33 percent more tumors together

Demand on the rise for MR-guided radiotherapy, says new report Compound annual growth rate of 20 percent through 2028

Breast MR for cancer survivors may result in unnecessary biopsies No difference in sensitivity compared to mammography alone

SEC probes Siemens, GE and Philips over business with China Lawsuit alleges OEMs worked together to fix prices on medical equipment

Ezra launches direct-to-consumer full-body MR scanning program Full-body imaging for $1,950 or single-region starting at $675

FDA okays Philips' MR-only radiotherapy simulator, MRCAT pelvis Create treatment plans for bladder, rectal, anal and cervical cancer

Bruker and the Champalimaud Foundation to develop first 18 Tesla UHF MR scanner Enable discovery of new contrast mechanisms

Helium shortage could have deflating effect on MR industry Party City cites shortage as contributor to 45 stores closing

Whole body MR may support faster, less expensive cancer treatment planning A single scan for planning and staging, but challenges remain

MR method could spare patients with skull lesions from CT, says study Could benefit children and pregnant women

Making the 'virtual biopsy' a reality with MR spectroscopy

From the November 2018 issue of DOTmed HealthCare Business News magazine
Story Continues Below Advertisement


Special-Pricing Available on Medical Displays, Patient Monitors, Recorders, Printers, Media, Ultrasound Machines, and Cameras.This includes Top Brands such as SONY, BARCO, NDS, NEC, LG, EDAN, EIZO, ELO, FSN, PANASONIC, MITSUBISHI, OLYMPUS, & WIDE.

Challenges and Solutions
Despite thousands of publications demonstrating the accuracy and diagnostic value of MR spectroscopy, this promising technique has not been fully utilized in clinical practice due to two primary issues: 1) data acquisition challenges, 2) lack of integration of data analysis into the clinical pipeline.

Unlike MR imaging sequences where the whole brain is acquired, MR spectroscopy is like a virtual biopsy where a region of interest must be selected. This raises some challenges to technologists, though advances in technology (such as improvements to automated shimming algorithms) have largely eliminated the need for time-consuming manual adjustments.
The development of more advanced MR spectroscopy sequences, such as chemical shift imaging, also allows for greater spatial resolution and allows for post-hoc reconstruction of data from select regions, albeit with some sacrifice of signal to noise.

However, these advances also raise the issue of standardization of methodologies, as the scientific literature is fragmented by different methods. The International Society of Magnetic Resonance in Medicine has risen to this challenge by establishing a MR spectroscopy consensus group in order to establish standardization of methods across all vendors.

Currently the only FDA-approved MR spectroscopy reconstruction tools from each vendor (e.g., GE FuncTool, Siemens Syngo, Philips FreeWave) utilize different methods of data reconstruction and do not provide depth of analysis.

On the one hand, research tools perform advanced processing methods and deliver high-quality quantification of metabolites (i.e., LCModel, jMRUI, AQSES, Tarquin). However these systems require expert knowledge to set up and operate, and are not well integrated into the clinical pipeline, or lack FDA approval (i.e., SIVIC). Advances in manufacturer software are underway, however. Third party software packages are seeking to fill this void (i.e. BrainSpec). These recent technological advances will help to translate MR spectroscopy into clinical, taking the technology of the future, into our present-day clinics.

Dr. Alexander Lin
About the author: Dr. Alexander Lin is the director of the Center for Clinical Spectroscopy at Brigham and Women’s Hospital and assistant professor of Radiology at Harvard Medical School. He received his doctoral degree in biophysics and molecular biochemistry at the California Institute of Technology and research fellowship at the National Institutes of Health. He has been developing research in the field of MR spectroscopy since 1997.

Back to HCB News
<< Pages: 1 - 2 - 3

MRI Homepage

You Must Be Logged In To Post A Comment

La publicité d'email
Développez la notoriété de votre marque
Enchères + Ventes Privées
Obtenir le meilleur prix
Acheter des équipement / pièces
Trouver le meilleur prix
Infos du jour
Lire Les dernières nouvelles
Consulter tous les utilisateurs DOTmed
Éthique concernant DOTmed
Voir notre programme d'éthique
L'or partie le programme de fournisseur
Recevoir des demandes PH
Programme de marchand de service d'or
Recevoir des demandes
Fournisseurs de soins de santé
Voir tous les outils des HCP (abréviation pour les professionnels de la santé)
Trouver / combler un poste
Parts Hunter +EasyPay
Obtenir des devis de pièces
Voir les utilisateurs récemment certifiés
Voir les utilisateurs récemment certifiés
Récemment évalué sur DOTmed
Voir les utilisateurs récemment certifiés
Central de location
Louer de l’équipement à moindre prix
Vendre des équipements / pièces
Obtenir le maximum d'argent
Service Technicians Forum
Trouver de l'aide et des conseils
Simple demande de propositions
Obtenir des devis pour des appareils
Expo Virtuelle
Trouver des services d'appareils
L'Access et l'utilisation de cet emplacement est sujet aux modalités et aux conditions du notre de nos MENTIONS LEGALES & DONNEES PERSONELLES
Propriété de et classe des propriétaires DOTmedà .com, inc. Copyright ©2001-2019, Inc.